Search - tctmd.com

Displaying 681 - 700 of 900

Sort: Relevancy | Date

Presentation

Stent Thrombosis with Ticagrelor vs. Clopidogrel in Patients with Acute Coronary Syndromes

Presenter: Philippe Gabriel Steg

August 02, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of DES

Presenter: Gregg W. Stone

July 30, 2013

Presentation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Presenter: B. A. Steinberg

July 24, 2013

Presentation

Heparin-bonded Covered Stents vs. BMS for Complex Femoro-popliteal Artery Lesions

Presenter: Johannes Lammer

July 16, 2013

Presentation

Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary PCI of the LAD

Presenter: Jochen W?hrle

July 09, 2013

Presentation

Interaction of Clopidogrel and Omeprazole

Presenter: Mary Ross Southworth, Robert Temple

June 28, 2013

Presentation

Clopidogrel with Aspirin in Acute Minor Stroke or TIA

Presenter: Yongjun Wang

June 26, 2013

Presentation

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

Presenter: M. Lamberts

June 12, 2013

Presentation

Heparin vs. Bivalirudin in Patients with NSTE-ACS Undergoing PCI

Presenter: Oskar Anger?s

May 23, 2013

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

Presentation

PARADOX: Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Presenter: Paul A. Gurbel

May 03, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

Presentation

Platelet Responsiveness to Clopidogrel Treatment After Peripheral Endovascular Procedures

Presenter: Stavros Spiliopoulos

April 25, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

Presentation

Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS

Presenter: Siddharth A. Wayangankar

April 19, 2013

Presentation Fellows 2013

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Presenter: Matthew Price

April 16, 2013

Presentation Fellows 2013

Antiplatelet Therapy for the Interventionalist

Presenter: Matthew Price

April 16, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

Advertisement

Stent Thrombosis with Ticagrelor vs. Clopidogrel in Patients with Acute Coronary Syndromes

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of DES

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Heparin-bonded Covered Stents vs. BMS for Complex Femoro-popliteal Artery Lesions

Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary PCI of the LAD

Interaction of Clopidogrel and Omeprazole

Clopidogrel with Aspirin in Acute Minor Stroke or TIA

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

Heparin vs. Bivalirudin in Patients with NSTE-ACS Undergoing PCI

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

PARADOX: Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Platelet Responsiveness to Clopidogrel Treatment After Peripheral Endovascular Procedures

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Antiplatelet Therapy for the Interventionalist

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content